<DOC>
	<DOCNO>NCT00150228</DOCNO>
	<brief_summary>The purpose study measure safety efficacy 12-week flexible dose strategy CP-526,555 compare placebo smoke cessation . Post-treatment follow-up smoking status one year randomization perform non-treatment extension Protocol A3051019</brief_summary>
	<brief_title>12 Week Evaluation Safety Efficacy Flexible Dose CP-526,555 Placebo Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Varenicline</mesh_term>
	<criteria>Subjects must smoke average least ten cigarette per day past year No period abstinence great three month past year Subjects history clinically significant cardiovascular disease Subjects uncontrolled hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>